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ABSTRACT: Polyethylene glycol (PEG)-coated nanopharmaceuticals
can cause mild to severe hypersensitivity reactions (HSRs), which can
occasionally be life threatening or even lethal. The phenomenon
represents an unsolved immune barrier to the use of these drugs, yet its
mechanism is poorly understood. This study showed that a single i.v.
injection in pigs of a low dose of PEGylated liposomes (Doxebo)
induced a massive rise of anti-PEG IgM in blood, peaking at days 7−9
and declining over 6 weeks. Bolus injections of PEG-liposomes during
seroconversion resulted in anaphylactoid shock (pseudo-anaphylaxis)
within 2−3 min, although similar treatments of naıv̈e animals led to
only mild hemodynamic disturbance. Parallel measurement of
pulmonary arterial pressure (PAP) and sC5b-9 in blood, taken as
measures of HSR and complement activation, respectively, showed a concordant rise of the two variables within 3 min
and a decline within 15 min, suggesting a causal relationship between complement activation and pulmonary
hypertension. We also observed a rapid decline of anti-PEG IgM in the blood within minutes, increased binding of
PEGylated liposomes to IgM+ B cells in the spleen of immunized animals compared to control, and increased C3
conversion by PEGylated liposomes in the serum of immunized pigs. These observations taken together suggest rapid
binding of anti-PEG IgM to PEGylated liposomes, leading to complement activation via the classical pathway, entailing
anaphylactoid shock and accelerated blood clearance of liposome−IgM complexes. These data suggest that complement
activation plays a causal role in severe HSRs to PEGylated nanomedicines and that pigs can be used as a hazard
identification model to assess the risk of HSRs in preclinical safety studies.
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Polyethylene glycols (PEGs), highly hydrated bulkypolymers in the 0.5−40 kDa range, are widely used toimprove the therapeutic efficacy of drug carrier lip-
osomes and proteins by extending their circulation time.
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An unresolved issue with such PEGylated nanopharmaceut-
icals is their recognition by the immune system manifested in
non-IgE-mediated (pseudoallergic) hypersensitivity reactions
(HSRs), an adverse event commonly called infusion reaction.1−7
PEGylated nanomedicines that have been reported to cause
such reactions include PEGylated liposomal doxorubicin
(Doxil/Caelyx),8 PEGylated G-CSF (pegfilgrastim, Neulasta),9
PEGylated erythropoetin (mono-mPEG-epoetin-β, Mircera),10
PEGylated recombinant human factor VIII (Adynovate),11 and
PEGylated phenylalanine ammonia lyase (pegvaliase-pqpz,
Palynziq),12 with at least three formulations withdrawn from
clinical use partly because of severe HSRs: PEGylated EPO-
mimetic peptide (peginesatide, Omontys),13 PEGylated urate
oxidase (pegloticase, Krystexxa),14 and a PEGylated IXa blocker
RNA aptamer (pegnivacogin, Revolixys).15
The symptoms include shortness of breath, facial redness and
swelling, chest pain, back pain, flashing, rash, chills, panic, and
fever that mostly arise shortly after the first treatment, although
reactions starting later or after repeated treatments are also
observed. In most cases the problem spontaneously resolves or
can easily be controlled; however, occasionally, the reaction can
escalate into pseudo-anaphylaxis, a severe, occasionally lethal
form of infusion reactions resembling anaphylaxis without IgE
playing a role. It is also known as anaphylactoid reaction, or
anaphylactoid shock.
Such HSRs with occasional pseudo-anaphylaxis are not
limited to PEGylated drugs but arise from a great variety of
i.v. medications, including micellar drugs, contrast agents,
biologicals, enzyme therapies, iron compounds, and even small
molecules.3,7 The phenomenon presents substantial clinical,
regulatory, and industrial concern, yet its immune mechanism is
far from being understood more than 100 years after the
discovery of anaphylaxis.5 Prediction of severe reactions is
uncertain at present, and their prevention and treatment are still
empirical and symptomatic.1−7
In order to better understand these reactions and help their
prediction and prevention, the present study used the porcine
complement activation-related pseudoallergy (CARPA)
model,16−19 which was shown previously to display typical
symptoms of cardiac anaphylaxis,16 whereupon the cause of
sudden death is shock with cardiac arrest. We used the model for
uncovering the immune mechanism underlying the HSRs to
PEGylated drugs, taking PEGylated liposomal doxorubicin
(Doxil/Caelyx) and its drug-free formulation, placebo Doxil
(Doxebo)20 as model agents. By providing evidence for a causal
relationship among the induction of anti-PEG antibodies,
complement activation, and pseudo-anaphylaxis, the present
data highlight themechanism of Doxil-induced severe HSRs and
use of the pig model in understanding and predicting this type of
immune toxicity of PEGylated nanopharmaceuticals.
RESULTS AND DISCUSSION
Immunogenicity of Doxebo. A single i.v. treatment of pigs
with low (0.1 mg phospholipid (PL)/kg) Doxebo led to a
massive rise of anti-PEG IgM and a parallel smaller rise of anti-
PEG IgG antibodies (Abs) (Figure 1). Panels A and B show the
titers on linear and logarithmic scales, respectively, the latter
amplifying the lower region of titer changes. The rise of Abs
started on day 3 following treatment, and the titers reached a
peak between days 7−9 and returned to close to baseline after
4−6 weeks. Essentially similar, although less expressed titers
were obtained when whole Doxebo was used as antigen in the
ELISA (data not shown).
A further observation in these experiments (visible only in
Figure 1B) was that the anti-PEG IgM/IgG levels were not zero
at baseline (time 0), indicating the presence of pre-existing
(natural) anti-PEG antibodies. The anti-PEG IgM titer
substantially varied in animals within the 20−1000 unit range,
IgM being in an order of magnitude higher range than IgG
(Figure 1B, y axis, color-matched error bar endings). Yet another
unexpected finding in Figure 1B was that the initial titers of both
anti-PEG IgM and IgG dropped at days 1−2 after immunization
with Doxebo.
Clearance of anti-PEG IgM Has the Same Time Course
as That of Infusion Reactions. The experiment in Figure 1B
showed the decline of anti-PEG IgM and IgG within a day
following immunization with Doxebo, although the exact
kinetics of this decline remained unresolved on a shorter time
course. Since the HSR to Doxil occurs on a time scale of
minutes,20 a question of particular interest to explore was the
possible coincidence of these changes. Accordingly, in the next
series of experiments naıv̈e pigs were bolus-injected with Doxil,
and we measured both the rise of pulmonary arterial pressure
(PAP) (a measure of HSR, Figure 2A) and the level anti-PEG
IgM in the blood (Figure 2B and C) on the minute time scale. In
keeping with earlier data20 bolus injection of Doxil led to a
Figure 1. Immunogenicity of Doxebo with anti-PEG Ab titers
presented on both linear (A) and logarithmic (B) scales. Units are
defined in the Materials and Methods. Points represent median ±
interquartile range (IQR); titers from n pigs specified above the
curves at each time point in panel A. The n = 19 value at baseline is
explained by our combination of Abmeasurements in immunized (n
= 12) and nonimmunized (n = 7) pigs only at this time.
Nonimmunized pigs showed no elevation of Ab titers. Subjecting
these data to the Kolmogorov−Smirnov test did not show a
Gaussian distribution of titers at all days, hence the median ± IQR
presentation. The Kruskal−Wallis test followed by Dunn’s multiple
comparison indicated a significant difference relative to baseline on
each day from 3 to 14 (*, P < 0.05 or **, P < 0.01). Details of the
ELISA are described in the Materials and Methods.
ACS Nano Article
DOI: 10.1021/acsnano.9b03942
ACS Nano 2019, 13, 9315−9324
9316
significant rise of PAP within 2 min, and the values returned to
baseline within 7−10 min (Figure 2A). Similar treatment of
animals with Doxebo in an earlier study20 had similar results,
although milder pulmonary reaction (inset in Figure 2A). Of
great surprise, the blood levels of anti-PEG IgM fell in the same
time window as the HSR occurred with clear separation into two
phases; a rapid plunge within 1 min was followed by a slow
decline over 15 min (Figure 2B). The latter process was
consistent and reproducible in 5 pigs (Figure 2C), allowing
highly significant logarithmic curve fitting (R2 = 0.997) typical of
first-order biological reactions. Importantly, correlating the anti-
PEG IgM titer changes with pulmonary hypertension also
showed a highly significant correlation (R2 = 0.97, Figure 2D).
These data taken together provide quantitative evidence for a
causal relationship between the decline of naturally occurring
anti-PEG IgM and Doxil-induced HSRs.
Amplified Reactogenicity of PEGylated Liposomes in
Pigs Immunized with Doxebo. If anti-PEG IgM plays a
causal role in Doxil-induced HSRs, as suggested by the data in
Figure 2, intentional elevation of these Abs by way of
immunization with Doxebo (Figure 1) is expected to increase
the reactogenicity of PEGylated liposomes. The experiments
shown in Figure 3 proved this prediction with unexpected
power. Bolus injections of Doxebo and Doxil in 5 immunized
pigs led within 2 min to life-threatening HSR in one and lethal
pseudo-anaphylaxis requiring resuscitation in 4 animals,
regardless of the timing of the test within the 2−6-week window
of seroconversion. As illustrated with the surviving animal in
Figure 3A, the PAP considerably increased in both amplitude
and duration compared to that seen in naıv̈e animals (Figure
2A), and we observed significant SAP and heart rate (HR)
changes even after repeated injections of liposomes (Figure 3A).
This implies loss of tachyphylaxis (self-tolerance), which is a
characteristic feature of Doxil reactions in naıv̈e pigs and is
thought to be due to depletion of natural antibodies,20 for which
we obtained evidence in Figure 2B and C. Thus, the
consumption of reactive antibodies during the first reaction
was not enough to deplete them to nonreactive levels. Figure 3B
illustrates the deadly pseudoanaphylaxis with maximal rise of
PAP and shock developing within 2 min. The panel also
illustrates the moments of resuscitation with cardiac massage
and epinephrine, resulting in an overshot of SAP. Figure 3C
shows that these severe reactions were associated with extensive
flushing and rash within 3 min.
Regarding the dose−effect relationship between anti-PEG
IgM and HSRs in immunized pigs, apart from the need or no
need for resuscitation, the reactions were quantitatively
indistinguishable regardless of the actualsignificantly ele-
vatedtiters of anti-PEG IgM at the time of the experiment.
This suggests that the significant correlation between anti-PEG
IgM and HSR obtained for naıv̈e animals (Figure 2D) is not
applicable in immunized pigs, as the amount of anti-PEG IgM in
blood far exceeds the plateau of the dynamic range of dose−
effect relationship, whose exact limits remain to be determined.
Evidence for a Role of Complement Activation in
PEGylated Liposome-Induced Pseudo-Anaphylactic
Shock in Immunized Pigs. The data in Figure 3 reveal
effective sensitization of animals for PEGylated liposome-
induced HSRs by immunization-induced rise of anti-PEG
IgM, which is consistent with a causal role of these Abs in the
phenomenon. As for the exact mechanism of the cause−effect
relationship, considering that antigen-bound IgM is one of the
Figure 2. Hemodynamic changes and plasma anti-PEG IgM levels in (naıv̈e) pigs injected with PEGylated liposomes. (A) Pulmonary
hypertensions caused by bolus injection of 0.1 mg PL/kg Doxil. Points represent median ± IQR, n = 5. Friedman test followed by Dunn’s
multiple comparison test showed the 1−4 min values were significantly different from baseline (**, P < 0.01 or *, P < 0.05). The inset
exemplifies the effect of Doxebo, reported in ref 20. (B) Plasma anti-PEG IgM titers as a function of time following injection of 0.1 mg/kgDoxil.
Typical values in 1 of 5 pigs. (C) Plasma anti-PEG IgM following injection of 0.1 mg/kg Doxil, % of 1 min readings, mean± SEM, n = 5. One
phase logarithmic curve fitting gave an R2 of 0.997, which is highly significant. (D) Correlation between the relative changes of anti-PEG IgM
titer and pulmonary arterial pressure following injection of 0.1 mg/kgDoxil, with the 1min readings taken as baseline. Values aremean± SEM,
n = 5. Pearson R2 = 0.966 indicates highly significant correlation.
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most powerful activators of the complement system via the
classical pathway, and that there is a large body of evidence for
the CARPA theory, i.e., that complement activation plays a
causal role in many HSRs (Supporting Table 1), complement
activation represents an obvious link between anti-PEG IgM and
HSR. However, such a link has had only indirect experimental
support to date, and the elevation of complement activation
byproducts in pig blood during HSRs has never been
shown.16−21
To fill this gap of information, we measured the levels of
porcine soluble complement terminal complex (sC5b-9) in the
plasma of immunized pigs during the first Doxebo-induced
massive hemodynamic disturbance (Figure 3A and B). Figure
4A shows that the pulmonary hypertension in these animals was
closely paralleled by a rise of sC5b-9 in blood, and, consistent
with the fact that sC5b-9 is the final product of the complement
activation cascade, its peak at about 3 min was slightly delayed
relative to the peak of the PAP curve. At this time the rise of
Figure 3. Reactogenicity of PEGylated liposomes in pigs immunized with Doxebo. (A) Hemodynamic changes in one out of 5 animals, showing
severe but not lethal responses to repetitive injections of the specified liposome doses 4 weeks after immunization. (B) pseudo-anaphylactic
shock in another pig illustrating the reaction of 4 out of 5 immunized pigs tested in the 2−6-week interval after immunization. In real-time
hemodynamic tracings, the large-amplitude noise coincided with cardiac massage. (C) Abdominal region of the skin before (“control”) and 3
min after the injection ofDoxebo, showing confluent skin flushing and rash observed in all 5 pigs. The objects in the pictures include a three-way
stopcock connected to a pressure transducer and the syringe used to inflate the spinnaker balloon of the Swan-Ganz catheter (see Materials and
Methods).
Figure 4. Doxebo-induced complement activation (sC5b-9) and pulmonary hypertension (PAP) in pigs immunized with Doxebo. (A) Time
course of PAP (red) and concurrent sC5b-9 (blue) changes following liposome challenge. Points representmedian± IQR in 4 pigs where blood
samples could be collected. Both PAP and sC5b-9 values were statistically different from their baseline (0 min) at *P < 0.05 and **P < 0.01,
obtained with the Friedman test followed by Dunn’s multiple comparison test. (B) Correlation between the area under the curve (AUC) values
of PAP and sC5b-9 during 10 min by the Pearson correlation test (P = 0.07, R2 = 0.864).
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sC5b-9 was significant relative to baseline, and the correlation
between PAP and sC5b-9 was strong when the areas under the
curve (AUC) of complement and PAP responses were analyzed
by linear regression (Figure 4B). These data therefore support a
causal relationship between complement activation and HSR.
Ex Vivo Evidence for Splenic Production of Liposome-
Binding Anti-PEG IgM. Further questions raised by the above
results are the organ source of anti-PEG IgM and themechanism
of its rapid clearance. In an experiment addressing these
questions we prepared spleen cell suspensions from an
immunized and a control pig on day 9 postimmunization and
measured by flow cytometry the binding of Doxil to IgM+ B cells
in vitro. The clearly discernible increase of Doxil+ cells in the
upper right gates in Figure 5C vsA indicates the binding of Doxil
to IgM+ cells even in control animals. Most noticeably, the cell
count of IgM+/Doxil+ cells tripled in immunized animals vs
control (Figure 5D vs C), indicating significant proliferation of
Doxil-binding cells in immunized pigs. These observations are
consistent with the presence of Doxil-binding anti-PEG IgM on
the surface of normal (naıv̈e) porcine splenocytes and significant
increase of these cells following immunization. Liberation of
these Abs into the circulation in naıv̈e animals may be one
source of natural anti-PEG IgM in the blood of pigs, while the
increased release of these Abs into the blood explains the
elevated anti-PEG IgM in immunized pigs. Furthermore, the
binding of Doxil to these Abs on B cells provides evidence for the
capability of Doxebo/Doxil to bind to these Abs in the
circulation. These findings and explanations taken together
support the proposal that the binding of anti-PEG IgM to
Doxebo/Doxil in blood explains complement activation, which
entails anaphylatoxin production and opsonization of liposomes.
The former process explains the HSRs, while the latter is
consistent with the first-order removal of anti-PEG IgM by the
mononuclear phagocyte system observed in Figure 2B and C,
most likely as single or multiple liposome−Ab complexes.
In Vitro Evidence for Increased Complement Activa-
tion by Doxil in Immunized Pig Sera. The rise of sC5b-9
during massive cardiopulmonary distress in immunized animals
(Figure 4A) was significant, but relatively small (2-fold), so we
sought other, independent evidence for complement activation
by Doxil in pig blood. As shown in Figure 6, incubation of Doxil
with immunized vs naıv̈e pig serum led to significantly increased
C3 consumption in the immune serum. Although the effect of
zymosan was also higher in the latter serum, the relative change
was much greater with Doxil, which is consistent with classical
pathway complement activation due to anti-PEG IgM binding.
CONCLUSIONS
Mechanism of HSR to PEGylated Nanomedicines:
Piecing the Steps Together. On the basis of a long list of
evidence for a causal role of complement activation in certain
liposome-induced HSRs (Supplement Table 1) we proposed
earlier that CARPA represents a major mechanism of infusion
reactions to a variety of nanoparticulate drugs and agents.21,22
However, recently, the role of complement in infusion reactions
has been questioned23 on the basis of an experiment that showed
no complement activation by a polystyrene nanoparticle in pig
blood in vitro, although it caused pulmonary reactions in pigs in
vivo.24 Although the validity of these in vitro data and the
generalization of conclusions was debated,25,26 the ultimate
question, what is the contribution of complement activation to
nanoparticle-induced cardiopulmonary distress of pigs vis-a-̀vis
other mechanisms, remained open. This question is particularly
relevant for Doxil, since it was shown to activate complement in
man both in vitro27 and in vivo,28 but in cancer patients infused
with this drug, only strong complement activation could be
associated with HSRs.28 Furthermore, direct evidence for
complement activation in pigs behind the HSRs to Doxil has
never been presented previously. Our present data showing
significant correlation between pulmonary hypertension and rise
of sC5b-9 in the blood of animals sensitized for Ab-mediated C
activation represent direct evidence that complement activation
can play a causal role in the pigs’ cardiopulmonary distress. In
Figure 5. Effect of immunization with Doxebo on Doxil binding to
splenic B cells. Spleen cells taken from an immunized and a control
animal 9 days after immunization were exposed to FITC-labeled
anti-IgM and fluorescent Doxil in vitro, and the fraction of cells
binding FITC-IgM and/or Doxil were determined in a flow
cytometer. Panels A−D show the distribution of cells displaying
different degrees of IgM and Doxil-specific fluorescence in
immunized and control animals. The upper right quadrant is a
gate on IgM+/Doxil+ cells. Str-FITC, streptavidin-FITS
Figure 6. Acceleration of complement activation by anti-PEG IgM in
pig serum in vitro. Doxil (3 mg PL/mL) and zymosan (0.3 mg/mL)
were incubated with the serum of a Doxebo-immunized pig (titer:
36,843) and that of a control (naıv̈e) pig (titer: 122) at 37 °C for 45
min, and C3 consumption was measured by Quidel’s Pan C3 assay.
Immunization was the same as in Figure 1.
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addition, the acceleration of cardiovascular distress to pseudo-
anaphylaxis in immunized animals displaying high anti-PEG
IgM titer in blood, taken together with the increased C3
conversion by Doxil in immune vs naıv̈e pig serum and the
accelerated clearance of anti-PEG IgM on the same time course
as complement activation and the cardiopulmonary reaction
proceeds, suggests a causal relationship not only between C
activation and pulmonary reaction but also between anti-PEG
IgM levels in blood and complement activation. These processes
pieced together suggest the comprehensive reaction scheme in
Figure 7, illustrating the sequence of reaction steps along an
immuno-circulatory axis: first the binding of Abs to liposomes
causing complement activation, liberation of anaphylatoxins and
other complement cleavage products, and their stimulatory
effects on allergy-mediating innate immune cells entailing the
secretion of vasoactive and inflammatory mediators, which are
responsible for the symptoms of HSRs.
In pigs, pulmonary intravascular macrophages (PIM cells) are
l ike ly to play a centra l ro le in sens i t iz ing the
model,17−20,23−25,39−41 but the involvement in HSRs of other
anaphylatoxin-sensitive and/or particle-scavenging secretory
cells (Kupffer cells, mast cells, dendritic cells, platelets, and
granulocytes) cannot be excluded either, just like the
contribution of complement-independent stimulation of these
cells, referred to as complement-independent pseudoallergy
(CIPA)25,29 (Figure 7). These concurrent stimulatory effects are
delineated by the “double-hit” hypothesis proposed for Doxil-
induced HSRs in pigs earlier,20 which can be extended to
“multiple hit” by other potential stimulatory signals on innate
immune cells, as illustrated in Figure 7. It should be noted that
phagocytosis of nanoparticles, as suggested by the “rapid
phagocytic response” hypothesis,23,24 represents another
possible contributor mechanism of HSRs, but is likely to apply
for C3b/iC3b/C3dg-opsonized nanoparticles26 only to the
extent that phagocytic cells can internalize them within 2 min.
The idea of complement-independent rapid phagocytosis
remains to be proven;23 however, it is unlikely to apply to
PEGylated liposomes, whose phagocytosis is known to be
inhibited by the PEG coating.
Explanations for Anti-PEG IgM Clearance. The rapid
decline of anti-PEG IgM titer in the plasma of naıv̈e pigs within
the first minute after Doxil injection (Figure 2B) may have ex
vivo and in vivo reasons, including competitive inhibition of anti-
PEG IgM capture by free liposomes in the ELISA plate and IgM-
induced polyvalent binding of multiple vesicles in vivo, entailing
aggregation and capillary sequestration. These possibilities need
further investigations. Nevertheless, the subsequent first-order
decay of anti-PEG IgM within 10−15 min that can be modeled
by a near-perfect logarithmic equation reflects a biological
process whose rate is proportional to the amount that is left. In
our case this process is most likely scavenging of liposome−IgM
complexes by cells of themononuclear phagocyte system (MPS)
with or without phagocytosis, a phenomenon known as
accelerated blood clearance (ABC).30−35
The Concept of “Primary ABC”. In ABC, studied for nearly
two decades mainly in murine models,30−35 the rapid clearance
of liposomes has been attributed to the binding of anti-PEG IgM
to the vesicles, entailing complement activation, opsonization,
and rapid clearance by the MPS. These anti-PEG Abs were
shown to be formed in splenic marginal zone B cells via T-cell
independent immunization by a prior injection of PEGylated
liposomes.32−35 It is therefore a fundamental difference between
the above “classical” ABC and our observations on rapid anti-
PEG IgM clearance that the latter process occurs already after
the first injection of liposomes; there is no priming (Figure 2B
and C). Assuming that the anti-PEG IgM undergoing rapid
clearance was liposome-bound, the finding suggests that
preexisting, naturally occurring anti-PEG IgM can similarly
Figure 7. Comprehensive mechanistic scheme of pseudoallergic infusion reactions to Doxil and other PEGylated nanoparticles: known and
hypothetical pathways of the reaction cascade. PEGylated liposomes bind anti-PEG Abs, which activate complement via the classical pathway
(CP). The liberated complement cleavage products stimulate a variety of innate immune and blood cells (e.g., PIM cells, macrophages, mast
cells, basophils, granulocytes, platelets) via different receptors, illustrated with color-coded arrows and surface shapes for different receptors.
These signaling pathways represent CARPA, but allergy-mediating phagocytic cells could also be activated without the involvement of
complement, referred to as complement-independent pseudoallergy (CIPA). Outward arrows show the known secretory products that can
mediate allergic symptoms. Continuous and dotted lines represent known and hypothetical activation mechanisms. Abbreviations: ATR,
anaphylatoxin receptor; C3b “opsonin pathway”, mediated byC3b, iC3b, andC3d(g) viaCR1 (CD35), CR2 (CD21), andCR3 (CD11b/CD18)
(blue); “C1q-C1qR pathway” (brown); “MBL/ficolin-MBL-R pathway” (red); “terminal complement complex (C5b-9) direct stimulation
pathway” (blue); potential additional stimulation mechanisms include Fc-mediated IgG/IgM binding to FcγRIIB (CD32)/FcγR (CD351)
(violet); and PEG binding to patter recognition receptors (PRRs), e.g., Toll-like receptor 2 and/or 6 and/or other PRR, as a consequence of
mimicking pathogen-associated molecular patterns (PAMPs) (green).
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remove liposomes as the induced Abs in “classical” ABC. Thus,
the rapid decay of anti-PEG IgM shown in Figure 2B and C may
reflect “primary”ABCwithmany of the attributes of “secondary”
ABC. Accordingly, primary ABC and CARPA may represent
“two sides of the same coin”,35 raising the question of why HSR
was never reported during secondary ABC in rats and mice. The
most likely explanation is that these species have orders of
magnitude lower sensitivity for HSRs than pigs or hypersensitive
human.29,36 It is the high sensitivity of the pig model for HSRs
that enabled uncovering of this duality.
Direct Evidence for IgM Binding to Doxil. The specific
binding between PEGylated liposomes and anti-PEG IgM
during secondary ABC in murine models was inferred, among
others, from flow cytometric analysis of the binding of
fluorescence-labeled PEGylated liposomes to liposome-primed
spleen cells in vitro, which correlated with the production of anti-
PEG antibodies, determined by ELISA.37,38 In an effort to
reproduce this observation for the case of pig splenocytes
obtained from naıv̈e and immunized pigs in our study, we
carried out the flow cytometry experiments shown in Figure 5.
The data indicated the presence of liposome-bound anti-PEG
IgM on splenic B cells (even in naıv̈e animals), whose number
significantly increased after immunization, leading to increased
binding of Doxil. These ex vivo observations in cell culture are in
keeping with all in vivo results in pigs and point to splenic B cells
as a likely source of anti-PEG IgM in pigs as well.
Criticismof the PorcineModel.The pigmodel used in this
study has recently been claimed to be irrelevant to the average
human patient and is therefore misleading for assessing the risk
of nanomedicine-induced HSRs.23,39−41 The reasons for this
view included the difference of HSR rate in pigs and the average
human, different underlying immune mechanisms, and the
“globality” of cardiopulmonary reactions. To clarify possible
misunderstandings that led to the above conclusions, it seems
important to re-emphasize18,19,25 that the pig model is not a
traditional immune toxicology model where the toxicities of
drugs on the immune system are assessed in healthy animals to
predict possible adverse immune effects in immunologically
normal humans. Like other animal models of allergy, the pig
model is an allergic disease model, i.e., that of severe
hypersensitivity of a small percentage of people to certain i.v.
administered nanopharmaceuticals. Regardless of the under-
lying mechanism, the concordance with human symptoms (see
below) enables the model to serve for identif ying the hazard of
hypersensitivity reaction to the tested drug in the case of
hypersensitive patients. Also, certain cardiopulmonary and other
physiological changes are quantitative and highly reproducible
within the dynamic window of the test, where the adverse
response is dose dependent. This allows using the model for the
assessment of the risk that the tested drugs might cause HSR, to
study themechanism of these reactions and developmethods for
their prevention.
Clinical Relevance of the Porcine CARPA Model. In
keeping with the above claims on human relevance, our
observations in the pig model show significant concordance
with some recent clinical trial data. Namely, the “RADAR” and
“REGULATE-PCI” trials with pegnivacogin (Revolixys kit)42,43
were stopped because of life-threatening HSRs. The tested
PEGylated aptamer caused anaphylaxis in 3/640 (0.46%) and
10/1605 (0.62%) patients, and reactions were observed
exclusively in those who had high levels of preformed anti-
PEG antibodies.42,43 Importantly, the indications of comple-
ment activation (rises of C3a, Bb, drop of CH50) included C4d,
a biomarker of classical pathway complement activation.42,43 In
agreement with the conclusion in the present study, the authors
of the above-mentioned clinical study suggested anti-PEG Ab-
triggered complement activation (i.e., CARPA) as the under-
lying cause of anaphylactic reactions, although they assign the
reactions to anti-PEG IgG, rather than anti-PEG IgM (which
was not measured). In another clinical study on the frequent and
severe HSRs to pegloticase (Krystexxa), a PEGylated recombi-
nant porcine enzyme (uricase) used for the treatment of
refractory gout, the HSRs were shown to be correlated with the
preexisting and induced anti-PEG Abs and rapid loss of the
drug’s efficacy.14,44 Yet another testimony to the clinical
relevance of the pig model is the recent FDA approval of a
transthyretin-directed small inhibitory RNA-containing nano-
particle (patisiran, Onpattro), whose safe administration
protocol was developed, in part, using the porcine CARPA
model.45
Perspective. This study provided experimental support for
the concept that PEGylated liposome-induced CARPA, whose
worst manifestation is pseudo-anaphylactic shock, proceeds
along the complement−circulatory system axis, via acute
cascadic activation of innate humoral and cellular immunity.
This information may help to better understand and, hence,
more efficiently predict and prevent HSRs to PEGylated and
other nanopharmaceuticals. Furthermore, the listed evidence of
concordance between the physiological and immune responses
to PEGylated nanoparticles in pigs and humans, as well as the
example of using the model by the biopharma industry, provides
strong support for the human relevance and use of the porcine
CARPA model for hazard identification in preclinical safety
studies.
MATERIALS AND METHODS
Drugs and Chemicals. Commercial Doxil (Caelyx) was obtained
from the pharmacy of Semmelweis University (in this paper we refer to
Doxil, as the two names represent the same drug). It contains
doxorubicin, 2 mg/mL (4.22 mM); fully hydrogenated soy
phosphatidylcholine (HSPC), 9.58 mg/mL; cholesterol, 3.19 mg/
mL; 2K-PEG-DSPE (N-carbamylpoly(ethylene glycol methyl ether)-
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine triethylammonium
salt with a polyethylene glycol moiety of average molecular mass of
2000 Da, 3.19 mg/mL; ammonium sulfate,∼0.2 mg/mL; histidine (10
mM, pH 6.5); and sucrose (10%). Total phospholipid: 12.8 mg/mL
(13.3 mM). Cholesterol was purchased from Avanti Polar Lipids Inc.
(Alabaster, AL, USA), mPEG2000-DSPE was from NOF, and HSPC
was from Lipoid Inc. (Ludwigshafen, Germany). All lipids had a purity
of ≥97%. Zymosan, Dulbecco’s phosphate-buffered saline (PBS)
without Ca2+/Mg2+ and bovine calf serum, and biotin-labeled goat
polyclonal anti-IgM were from Sigma Chemical Co. (St. Louis, MO,
USA). Doxorubicin was from TEVA Pharmaceuticals (Petach Tikva,
Israel). Streptavidine-FITC was from Molecular Probes. FACS Lysing
solution and paraformaldehyde were from BD. The MicroVue Pan C3
kit (Quidel Corp, cat. no. 20261) was obtained from TECOMedical
(Sissach, Switzerland). Anti-PEG mouse monoclonal IgM (ANPEG-1)
was obtained from ANP Technologies, Inc. (Newark, DE, USA).
Preparation of Doxebo. The preparation and characteristics of
Doxebo were described earlier.20 In brief, the freeze-dried lipid
components of Doxil (listed above) were hydrated in 10 mL sterile
pyrogen-free normal saline by vortexing for 2−3 min at 70 °C to form
multilamellar vesicles (MLVs). TheMLVs were downsized through 0.4
and 0.1 μm polycarbonate filters in two steps, 10 times through each,
using a 10mL extruder barrel fromNorthern Lipids (Vancouver, British
Columbia, Canada) at 62 °C. Liposomes were suspended in 0.15 M
NaCl/10 mM histidine buffer (pH 6.5). The size distribution (Z-
average: 81.17 nm) and phospholipid concentration of Doxebo (12.6
mg/mL) were determined as described.20
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Determination of Bacterial Endotoxin (LPS) in Liposomes.
The LPS content of liposomes prepared for this study was determined
by a limulus amebocyte lysate assay (PYROGENT Plus, Cambrex Bio
Science, East Rutherford, NJ, USA), after dissolving (96% ethanol) and
separating (ultrafiltration using a 20 kDa cutoff membrane) the lipids
from LPS. Acceptance criteria as pyrogen-free were ≤0.5 EU/mL
(0.01−0.25 ng LPS/mL).
Pig Studies. The details and evaluation of the porcine “CARPA
model” were described in several studies earlier.17−20,44 In brief, mixed
breed male Yorkshire/Hungarian White Landrace pigs (2−3 months
old, 18−22 kg) were obtained from the Animal Breeding and Nutrition
Research Institute, Herceghalom, Hungary. Animals were sedated with
Calypsol/Xilazine and then anesthetized with isoflurane (2−3% in O2).
Intubation was performed with endotracheal tubes to maintain free
airways and to enable controlled ventilation if necessary. The animals
were breathing spontaneously during the experiments. Surgery was
done after povidone iodine (10%) disinfection of the skin. In order to
measure the PAP, a Swan−Ganz catheter (AI-07124, 5 Fr. 110 cm,
Arrow Internat Inc.) was introduced into the pulmonary artery via the
right external jugular vein. Additional catheters were placed into the left
femoral artery to record the systemic arterial pressure (SAP), into the
left external jugular vein for saline and drug administration, and into the
left femoral vein for blood sampling.
The test samples (liposome suspensions) and zymosan were injected
into the animals as a bolus (<10 s) into the pulmonary artery or in an
infusion via the left external jugular vein. The experiment typically
involved bolus injection of 0.1 mg PL/kg Doxebo, followed by a similar
dose of Doxil (0.1 mg PL/kg), then a larger dose of Doxil, and, finally,
0.1 mg/kg zymosan as positive control. At the end of the experiments
animals were sacrificed with Euthasol and concentrated potassium
chloride.
Monitoring of Different Physiological Changes during
CARPA. The area under the PAP and SAP change (AUC) was





















where “n” represent time and “x” is the last minute (typically 10) of
observation. PAP0 is the PAP value immediately before treatment
(equivalent with baseline).
Pretreatment (Immunization, Sensitization) of Pigs. Immu-
nization with Doxebo on day 0 consisted of infusion of Doxebo (0.1 mg
PL/kg) in pigs via their ear vein (suspended in 20 mL of saline) at a
speed of 1 mL/min over 20 min.
Blood Samples. Blood samples for Ab analysis were taken from the
ear vein before pretreatment and then at different times specified in the
Results. Anticoagulation was done with either EDTA or hirudin, by
using the corresponding hirudin- or K3-EDTA tubes.
ELISA of Porcine sC5b-9. Porcine sC5b-9 determination was done
as described earlier.46 In brief, microtiter plates were coated with mouse
anti-human sC5b-9 ascites (clone aE11) and incubated for 1 h with
plasma containing 10 mM EDTA. The second Ab, biotinylated mouse
anti-human C6 (Quidel A219), was stained with streptavidin−
horseradish peroxidase (HRP) using ABTS and H2O2 substrate.
ELISA of Anti-PEG Antibodies. Polysorp (Nunc) plates were
coated with 1.25 μg/well DSPE-PEG2000 in 100 μL of bicarbonate
buffer (4.46 μM) (pH ∼9.0) overnight at 4 °C, followed by blocking of
the wells with 150 μL of PBS/0.05% Tween-20 + 2% bovine serum
albumin (BSA) at 37 °C for 1.5 h. Before and after blocking, wells were
washed two and three times with 300 μL of wash buffer containing
PBS/0.05% Tween-20 for 1 min, respectively. The EDTA-anti-
coagulated plasma samples were diluted by PBS/0.05% Tween-20 +
1% BSA in the 10−19 500-fold range and incubated in the wells for 1.5
h at 37 °C, with slow shaking. Wells were washed five times with 300 μL
of wash buffer for 1 min. After staining with 100 μL of HRP-conjugated
anti-porcine IgM (2000× dilution, Sigma) or IgG (800× dilution,
Sigma) for 1 h, wells were washed again five times with wash buffer as
mentioned. The antibodies were stained by incubation with 100 μL of
substrate solution (Neogen) containing 3,3′,5,5′-tetramethylbenzidine
(TMB) and hydrogen peroxide for 15 min in dark. The reaction was
stopped with 50 μL of 2 N H2SO4, and A450 was read with a Fluostar
Omega 96-well plate reader (BMG Labtech, Ortenberg, Germany).
The titer unit was defined as the dilution at which the blank-corrected
OD was 0.1. The ELISA was validated as described in the Supporting
Information (Figure S1).
Binding of Doxil to Splenic IgM Positive B Cells. A Doxebo-
immunized pig (see above) and a naıv̈e pig were sacrificed 9 days after
immunization, and their spleens were removed for flow cytometric
assessment of the binding of Doxil to anti-PEG IgM+ B cells. Single-cell
suspensions from spleen tissue slices were prepared by gentle
homogenization in Dulbecco’s PBS without Ca2+/Mg2+ supplemented
with 2% bovine calf serum and 2 mM EDTA. The latter medium was
sterilized by filtration, and the cell suspension was homogenized by
aspirations via a 21 G needle. Cells were centrifuged (20 °C, 500g, 8
min) and washed and suspended in the medium at 106 cells/mL. This
was followed by incubation with biotin-labeled anti-IgM and Doxil for
30 min at 4 °C. After washing, IgM-labeled cells were stained by
streptavidin-FITC for 20 min at room temperature (RT). Following
repeated washing, red blood cells were lysed by FACS Lysing solution
for 10min at RT. Finally, after a final washing, cells were resuspended in
1% paraformaldehyde. FACS analysis was done in a FACScan (BD),
and the data were analyzed by Kaluza software (Beckman Coulter). In
control staining tubes, cells were incubated without Doxil or without
Doxil and anti-IgM (just with biotin-FITC).
Measurement of Pig C3 Consumption in Vitro by ELISA. Pig
sera obtained from a naıv̈e and an immunized animal (day 7) were
incubated with Doxil and zymosan (activator/serum volume ratio was
1/3) for 45 min at 37 °C with shaking. Incubation was stopped by
adding 10 vol ELISA sample diluent complemented with 10 mM
EDTA, and the samples were measured for porcine C3 level using the
MicroVue Pan-Specific C3 reagent kit (Quidel Corp) according to the
manufacturer’s instructions. The 45 min values were compared to the
baseline, i.e., similar samples analyzed immediately after mixing the
activators with the serum (0 min). Consumption was calculated by 100
− (OD45 min/OD0 min × 100), where OD45 min and OD0 min are
absorbances at 450 nm at the specified times.
Statistical Methods. Normality was tested by the Kolmogorov−
Smirnov test. The anti-PEG Ab titers and PAP values at all time points
were compared to their baseline (0 min), and the significance of
differences was determined by nonparametric Kruskal−Wallis and
Friedman tests, followed by Dunn’s multiple comparisons, respectively.
To study the correlation between changes in the sC5b-9 values and PAP
AUC values in response to Doxebo/Doxil treatments 4−6 weeks
following immunization, we used Pearson analysis, preceded by testing
for normal distribution and outliers by Kolmogorov−Smirnov and
Grubb’s tests, respectively. A P-value of less than 0.05 was considered to
be statistically significant. Statistical analysis was performed by
GraphPad Prism software (GraphPad Software, La Jolla, CA, USA).
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